Biotech Company in Britain Secures $15 Million Funding for its Armored Cancer-Fighting Virus, Set to Commence Clinical Trials
In the fast-paced world of biotechnology, a British company named PsiOxus is making waves with its innovative approach to cancer treatment. Specializing in oncolytic virus technology, PsiOxus is poised to become a leader in the field of immuno-oncolytic therapies.
PsiOxus and Oncolytic Virus Technology
PsiOxus is renowned for its immuno-oncolytic virus technology, which primarily differentiates itself through the use of Enadenotucirev, a chimeric adenovirus. This virus is engineered for selective targeting and replication in tumor cells, with strong potential for inducing anti-tumor immune responses.
Key Differences from Other Oncolytic Virus Technologies
Compared to other oncolytic virus technologies, PsiOxus' approach offers several key advantages.
- Chimeric Adenovirus Platform: Enadenotucirev is derived by combining elements of two adenovirus serotypes, enabling enhanced tumor-specific infection and evasion of neutralizing antibodies.
- Systemic Delivery Capability: Enadenotucirev is designed to be delivered intravenously, targeting metastatic tumors, unlike many oncolytic viruses that focus on intratumoral injections and have limited systemic reach.
- Immuno-Oncolytic Effects: Beyond direct tumor lysis, PsiOxus emphasizes arming their virus to stimulate the immune system against cancer cells, making their approach a combined oncolytic and immunotherapy modality.
- Progress in Early-Stage Clinical and Translational Development: PsiOxus has conducted Phase I studies with Enadenotucirev showing safety and preliminary activity in solid tumors, placing it among industry leaders in early-stage clinical validation in this oncolytic virus class.
Aiming for Global Leadership
With a goal to become the world's leading immuno-oncolytic company, PsiOxus has signed a deal with Bristol-Myers Squibb. Under the terms of this deal, signed in December 2016, Bristol-Myers Squibb will pay PsiOxus a milestone payment of $15M (€13M). The potential total payment from Bristol-Myers Squibb to PsiOxus could rise to $936M (€795M) if the product's development and commercialization go well.
Subscribe to Our Newsletter for Biotech Updates
Stay informed about the latest biotech news by subscribing to our newsletter. We'll keep you updated on the exciting developments at PsiOxus and the broader biotech industry.
John Beadle, CEO of PsiOxus, is leading the company's charge towards this ambitious goal. Other companies in the biotech industry are also making strides in oncolytic virus technology, but PsiOxus' unique approach with a chimeric adenovirus optimized for systemic delivery and immune activation is setting it apart.
For more information about PsiOxus and its groundbreaking work, visit our website. Please note that the privacy policy for our newsletter subscription is not specified in this article.
[1] Reference for further reading [2] Another reference for deeper understanding [3] Yet another reference for comprehensive insights [4] And another reference for detailed information [5] Final reference for a holistic perspective
- PsiOxus, a British company in the biotech industry, specializes in oncolytic virus technology, using a chimeric adenovirus called Enadenotucirev for selective targeting and replication in tumor cells.
- The company's approach to cancer treatment, immuno-oncolytic therapy, offers advantages over other oncolytic virus technologies, such as enhanced tumor-specific infection, systemic delivery capability, and immuno-oncolytic effects.
- PsiOxus aims to become the world's leading immuno-oncolytic company and signed a deal with Bristol-Myers Squibb in December 2016, potentially earning up to $936M (€795M) if their product's development and commercialization are successful.
- Keep updated on the biotech industry and PsiOxus's groundbreaking work by subscribing to their newsletter. The company's CEO, John Beadle, leads their ambitious goal to set them apart from other companies in oncolytic virus technology.
